Ab&B Bio-Tech Forecasts Strong Revenue Growth and Narrowing Loss for 2025

Ab&B Bio-Tech CO., LTD. JS Class H ( (HK:2627) ) just unveiled an announcement.

Ab&B Bio-Tech CO., LTD. JS has issued a profit alert indicating that its 2025 revenue is expected to surge by about 72% to 90% year on year to between RMB446 million and RMB493 million, while its net loss should narrow by roughly 24% to 39% from RMB258.7 million in 2024. Management attributes the improved performance to tighter quality and cost controls, data-driven digital marketing, broader distribution coverage and early gains in operational efficiency despite higher listing expenses, signaling progress toward scaling its vaccine business and reducing losses for stakeholders.

The company reports a 100% qualification rate for product batches, which helped curb cost of sales and support margin improvement alongside more targeted promotion spending. Its expansion to an additional 232 disease control centers and 2,563 vaccination clinics in 2025 has increased geographic reach and sales, reinforcing its market position even as final audited results for the year remain pending and investors are urged to trade the shares with caution.

The most recent analyst rating on (HK:2627) stock is a Sell with a HK$47.00 price target. To see the full list of analyst forecasts on Ab&B Bio-Tech CO., LTD. JS Class H stock, see the HK:2627 Stock Forecast page.

More about Ab&B Bio-Tech CO., LTD. JS Class H

Ab&B Bio-Tech CO., LTD. JS is a China-based biotechnology company listed in Hong Kong that develops and manufactures vaccine-related products. The group focuses on smart manufacturing, strict quality management and an expanding distribution network that targets disease control centers and vaccination clinics across multiple regions in the domestic market.

Average Trading Volume: 251,981

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$20.73B

Find detailed analytics on 2627 stock on TipRanks’ Stock Analysis page.